TradeUP Acquisition Corp.
UPTDU
NASDAQ Capital Market9.78
USD
-0.24
- -
TradeUP Acquisition Corp.
UPTDU
(NASDAQ Capital Market)
Recent
price
9.78
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TradeUP Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in 2021 and headquartered in New York, New York. Originally formed to effect mergers, acquisitions, and business combinations, it completed a significant business combination in 2023 with Estrella Biopharma, Inc., a preclinical-stage biopharmaceutical company specializing in the development of T-cell therapies targeting blood cancers and solid tumors. The combined entity, now trading under the name Estrella Immunopharma, Inc., focuses on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies, including lead candidates EB103 and EB104, designed to improve outcomes for patients with B-cell leukemias, lymphomas, and solid tumors. Estrella Immunopharma also collaborates with Imugene Limited to research a combined treatment approach using EB103 and Imugene's oncolytic virus CF33-CD19t. Recent major changes include the completion of the business combination in September 2023, closing of Series A preferred stock financing and private placement raising approximately $23.11 million in cash to advance clinical programs. The company operates primarily in the biopharmaceutical industry in the US and Canada, with a focus on innovative cancer immunotherapies. This strategic shift from a SPAC to an operating biopharma company marks its latest and most significant transformation. TradeUP Acquisition Corp. was founded in 2021 and is headquartered in New York, NY.